乳糜微粒在动脉粥样硬化防治中的作用  

Role of chylomicron in the prevention and treatment of atherosclerosis

作　　者：蔡雅杰 范晓迪[2] 白瑞娜[1] CAI Yajie;FAN Xiaodi;BAI Ruina(Department of Cardiovascular Medicine,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China;Academy of Basic Medicine,Xiyuan Hospital,China Academy of Chinese Medical Sciences,Beijing 100091,China)

机构地区：[1]中国中医科学院西苑医院心血管科,北京市100091 [2]中国中医科学院西苑医院基础医学研究所,北京市100091

出　　处：《中国动脉硬化杂志》2023年第9期799-805,820,共8页Chinese Journal of Arteriosclerosis

基　　金：国家自然科学基金面上项目(82174216);中国中医科学院优秀青年科技人才(创新类)培养专项(ZZ13-YQ-005)。

摘　　要：乳糜微粒作为肠源性富含甘油三酯脂蛋白及其残余物的主要来源,可促进动脉粥样硬化病变的发生发展。因此,减少乳糜微粒及其残余物有望成为降低心血管疾病残余风险的有效方法之一。本文系统阐述乳糜微粒产生过程中的关键蛋白及其分子机制、中西医药物治疗进展,以期为动脉粥样硬化防治提供可靠的新思路。Chylomicrons,as the main source of intestinal triglyceride-rich lipoproteins and their remnants,can promote the occurrence and development of atherosclerosis.Therefore,reducing chylomicrons and their remnants are expected to be one of the effective methods to reduce the residual risk of cardiovascular disease.This review describes the key proteins in the production of chylomicrons and their molecular mechanisms,as well as the progress of Chinese and Western medicine therapy systematically in order to provide reliable new ideas for the prevention and treatment of atherosclerosis.

关 键 词：乳糜微粒 动脉粥样硬化 脂质代谢 

分 类 号：R543.5[医药卫生—心血管疾病]